Evidence map›Paper›PMID 41224821›Full record

ArticleScientific reports2025

In silico and in vitro evaluation of drug-like properties and anticancer potential of novel 5-fluorouracil derivatives.

Kristine Harutyunyan, Lyudmila Nersesova, Violetta Ayvazyan, Emmi Avagyan, Merirouz Melkumyan, Maksim Sargsyan, Stepan Tatikyan, Zaven Karalyan, Hranush Avagyan, Arthur Harutyunyan and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kristine HarutyunyanInstitute of Molecular Biology NAS of RA, Yerevan, 0014, Armenia.
Lyudmila NersesovaInstitute of Molecular Biology NAS of RA, Yerevan, 0014, Armenia.
Violetta AyvazyanInstitute of Molecular Biology NAS of RA, Yerevan, 0014, Armenia.
Emmi AvagyanCANDLE Synchrotron Research Institute, Yerevan, 0040, Armenia.
Merirouz MelkumyanCANDLE Synchrotron Research Institute, Yerevan, 0040, Armenia.
Maksim SargsyanCANDLE Synchrotron Research Institute, Yerevan, 0040, Armenia.
Stepan TatikyanCANDLE Synchrotron Research Institute, Yerevan, 0040, Armenia.
Zaven KaralyanInstitute of Molecular Biology NAS of RA, Yerevan, 0014, Armenia.
Hranush AvagyanInstitute of Molecular Biology NAS of RA, Yerevan, 0014, Armenia.
Arthur HarutyunyanScientific Technological Center of Organic and Pharmaceutical Chemistry NAS of RA, Yerevan, 0014, Armenia.
Gohar TsakanovaInstitute of Molecular Biology NAS of RA, Yerevan, 0014, Armenia.
Nelly BabayanInstitute of Molecular Biology NAS of RA, Yerevan, 0014, Armenia. n_babayan@mb.sci.am.

Funding

Science Committee of RA 24FP-3A057
6 · The paper itself

Abstract

The development of more effective and safer anticancer agents remains a critical focus in cancer therapy. While biologics are gaining attention, small molecules continue to play a significant role due to their versatility and cost-effectiveness. This study investigates the potential of synthesized 5-fluorouracil derivatives to improve its drug-like properties, as well as anticancer activity in human lung cancer cells. Among the synthesized compounds, two (2c and 3a) demonstrated greater cytotoxicity and selectivity toward A549 lung cancer cells compared to 5-FU. These derivatives did not induce oxidative stress but instead affected antioxidant enzyme activity, suggesting interference with cellular metabolism. Additionally, these derivatives shifted cells toward hypodiploidy, suggesting the presence of apoptotic cells, while 5-FU significantly increased A549 cell ploidy, a trait linked to cancer progression and treatment resistance. In silico predictions revealed improved pharmacokinetic properties for the 2c derivative and a low probability of hepatotoxicity or neurotoxicity compared to 5-FU. These findings suggest that 2c and 3a derivatives warrant further research as potentially safer and more effective alternatives to 5-FU.

Indexed as

Antineoplastic AgentsFluorouracilA549 CellsApoptosisCell Line, TumorCell SurvivalComputer SimulationHumansOxidative StressAntineoplastic AgentsFluorouracil5-FU derivativesCytotoxicityIn silico ADMETOxidative stressPloidySynthesisTwo-photon microscopy

Identifiers

PMID41224821
PMCPMC12612264

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.